CD8 T cells are a key component of the host adaptive immune responses that helps to eradicate invading virus and other cell-associated pathogens. The CD8 T cell responses to an acute infection consist of three well defined phases: naïve pathogen-specific T cells (CD8 N ) become activated and expand resulting in large numbers of effector cells (CD8 E ); the contraction of these CD8 E into memory cells (CD8 M ) once the infection is cleared; and the long-term maintenance of these CD8 M . If a secondary infection occurs, the CD8 M mount more vigorous and faster responses than CD8 N , which help to rapidly and efficiently control the infection. The prolonged maintenance of this pool of antigen-specific CD8 M can help protect from certain infections. Hence, one of the goals of vaccination is to generate CD8 M .
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CD4 T cell help (T H ) is essential for priming CD8 T cell responses to cell-associated, non-inflammatory antigens while being dispensable for responses generated to a variety of infectious pathogens. In several infectious models, T H is critical for the conditioning and/or maintenance of the CD8 M pool and/or their secondary expansion and differentiation into secondary effectors.
VACV is an orthopoxvirus (OPV) that was used as the vaccine that eliminated human smallpox, a highly lethal disease caused by the human-specific OPV variola virus (VARV). VACV is regarded as the golden standard of a highly effective vaccine. In addition to preventing smallpox, VACV is also effective as a vaccine against lethal mousepox, a disease caused by the mouse-specific OPV ectromelia virus (ECTV). We previously showed that in addition to antibodies, CD8 M induced by VACV immunization can fully protect susceptible mice from lethal mousepox [1] , suggesting that the establishment of a CD8 M pool is one of the mechanisms whereby the smallpox vaccine protects from pathogenic OPVs. However, during the course of VACV infection or immunization, the role of T H for the generation, maintenance and recall responses of the anti-VACV CD8 M remained controversial [2] [3] [4] [5] [6] . A possible explanation for these discrepancies may lie in the replicative capacity of the VACV strain used in different studies. Using a non attenuated VACV strain WR as the vaccine and ECTV as the pathogen, and by measuring polyclonal rather than transgenic CD8 T cells responses, we have recently shown that anti-VACV CD8 M generated in the absence of T H that expand and differentiate into CD8 E are as effective as helped CD8 M in their ability to protect from lethal ECTV infection [7] .
Consistent with some previous research, we found that wild type B6 mice and MHC-II-deficient mice (MHC-II 0/0 ), which lack MHC-II restricted T H, mounted similar CD8 T cell responses during the acute phase of VACV infection (i.e. 7 days post immunization), indicating that optimal primary CD8 T cell responses to VACV are T H independent. After virus clearance, the frequency of CD8 M
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Figure 1: Conditioning and maintenance of anti-VACV CD8 M and their protective capability to ECTV infection can develop without T H .
The primary CD8 T cell responses to VACV were similar between wild type B6 mice and MHC-II 0/0 mice. Functional CD8 M were maintained in MHC-II 0/0 mice even though at lower frequency. When cell numbers are adjusted, the unhelped CD8 M from MHC-II 0/0 mice were similarly potent at protecting mice from lethal ECTV infection as the helped CD8 M from wild type mice.
specific for the VACV immunodominant determinant TSYKFESV (also an immunodominant determinant of ECTV) declined faster in MHC-II 0/0 mice. However, most of the activation and memory markers were similar between the TSYKFESV-specific CD8 M from wild type and MHC-II 0/0 mice. Moreover, the unhelped CD8 M expanded and generated secondary CD8 M when maintained and boosted in the MHC-II deficient environment, and most of the activation and memory markers between the TSYKFESV-specific secondary CD8 M from wild type and MHC-II 0/0 mice were similar. The ultimate goal of CD8 M is protecting from disease. To test the protective potential of the unhelped CD8 M , we transferred secondary CD8 M from wild type and MHC-II 0/0 mice into B6.D2-(D6Mit149-D6Mit15) LusJ (B6.D2-D6) mice, a B6 congenic mouse strain that is susceptible to mousepox. Importantly, when adjusted to contain similar numbers of TSYKFESV-specific CD8 M , the unhelped CD8 M protected B6.D2.D6 mice as efficiently as helped CD8 M . Transferring as few as 4.5×10 4 helped or unhelped TSYKFESV-specific CD8 M significantly reduced the virus loads to similar lower levels and fully protected B6.D2-D6 mice from death. Thus, polyclonal anti-VACV CD8 M generated in the absence or in the presence of T H are similarly potent at protecting mice from lethal ECTV infection on a per cell basis.
Our results do not necessarily dispute that T H contribute to optimal maintenance of CD8 M as the CD8 M declined faster in MHC-II 0/0 mice than that in WT mice. Yet, it is possible that this faster decline was due to the general poorer health of MHC-II 0/0 mice, which are immunodeficent. Nevertheless, our work clearly shows that T H is not essential for the establishment of functional CD8 M or to confer CD8 M the capacity to protect from a lethal infection (Figure 1 ). Because VACV is used as a vaccine in humans, our results may help us to understand how this vaccine induces protective immunity in people.
